In the originally published version of this Letter, the authors Arthur In Fig. 1a (structure 4) of this Letter, the A-485 structure incorrectly included a sulfur atom (S) instead of a carbon (C) at the spiro centre. Figure 1 has been corrected online (see Supplementary Information to this Amendment for the original Fig. 1a, structure 4) . In Fig. 4d of this Letter, the units for enzalutamide (Enz) and A-485 were incorrectly listed as millimolar (mM) instead of micromolar (µM). Figure 4 has been corrected online. In Extended Data Fig. 7e of this Letter, the headings '−DHT' and ' + DHT' were missing from the top of the western blots; this figure has been corrected online.
The third sentence of the main text should have read: "This led to two confirmed hits, a hydantoin (Fig. 1a, 1 ) and a conjugated thiazolidinedione (Fig. 1a, 2 ), which were similar to the previously described hit that inhibited Rtt109 8 and the hit C375 6 , respectively", rather than "This led to two confirmed hits, a hydantoin (Fig. 1a, 1 ) and a conjugated thiazolidinedione (Fig. 1a, 2 ), which were similar to the previously described hits that inhibited Rtt109 8 and C375
6
, respectively. This has been corrected online.
Finally, the following sentence has been added to the 'Competing interests' statement: A.F.K. and M.A.P were consultants to Acylin at the time of the study. C.W. was an employee of BioDuro, which was contracted by Acylin at the time of the study.
